JP2016509018A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016509018A5 JP2016509018A5 JP2015557515A JP2015557515A JP2016509018A5 JP 2016509018 A5 JP2016509018 A5 JP 2016509018A5 JP 2015557515 A JP2015557515 A JP 2015557515A JP 2015557515 A JP2015557515 A JP 2015557515A JP 2016509018 A5 JP2016509018 A5 JP 2016509018A5
- Authority
- JP
- Japan
- Prior art keywords
- vegf
- pharmaceutical composition
- composition according
- polypeptide
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims 14
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims 11
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 claims 6
- 208000031513 cyst Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000027455 binding Effects 0.000 claims 5
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims 4
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims 4
- 230000000492 lymphangiogenic effect Effects 0.000 claims 4
- 230000037416 cystogenesis Effects 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 150000008574 D-amino acids Chemical class 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000001415 gene therapy Methods 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims 1
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 claims 1
- 208000002814 Autosomal Recessive Polycystic Kidney Diseases 0.000 claims 1
- 208000017354 Autosomal recessive polycystic kidney disease Diseases 0.000 claims 1
- 208000026372 Congenital cystic kidney disease Diseases 0.000 claims 1
- 206010011732 Cyst Diseases 0.000 claims 1
- 208000026292 Cystic Kidney disease Diseases 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 230000003907 kidney function Effects 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361764626P | 2013-02-14 | 2013-02-14 | |
| US61/764,626 | 2013-02-14 | ||
| PCT/GB2014/050436 WO2014125291A1 (en) | 2013-02-14 | 2014-02-14 | Agents which induce lymphangiogenesis for use in the treatment of cystic kidney disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016509018A JP2016509018A (ja) | 2016-03-24 |
| JP2016509018A5 true JP2016509018A5 (enExample) | 2017-03-16 |
| JP6261617B2 JP6261617B2 (ja) | 2018-01-17 |
Family
ID=50150722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015557515A Expired - Fee Related JP6261617B2 (ja) | 2013-02-14 | 2014-02-14 | 嚢胞性腎疾患の処置に使用されるリンパ管新生を誘発する作用物質 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20160000873A1 (enExample) |
| EP (1) | EP2956159A1 (enExample) |
| JP (1) | JP6261617B2 (enExample) |
| WO (1) | WO2014125291A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019195770A1 (en) | 2018-04-06 | 2019-10-10 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
| TWI725499B (zh) * | 2019-07-31 | 2021-04-21 | 優仕達資訊股份有限公司 | 用以定位行動裝置之天線系統 |
| AU2020358854B2 (en) | 2019-10-03 | 2026-08-13 | Atyr Pharma, Inc. | Compositions and methods comprising anti-NRP2 antibodies |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| ZA858044B (en) | 1984-11-01 | 1987-05-27 | American Home Prod | Oral vaccines |
| US5166059A (en) | 1987-06-16 | 1992-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy using gene fusions for genetic or acquired disorders |
| US5631237A (en) | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
| EP0783572B1 (en) | 1994-09-22 | 2005-04-27 | Licentia Ltd. | Promoter for the receptor tyrosine kinase, tie |
| US6645933B1 (en) | 1995-08-01 | 2003-11-11 | Helsinki University Licensing Ltd. Oy | Receptor ligand VEGF-C |
| US5792453A (en) | 1995-02-28 | 1998-08-11 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
| US20010034062A1 (en) | 2000-02-09 | 2001-10-25 | Scott Koenig | Antibody gene therapy with adeno-associated viral vectors |
| US8007790B2 (en) * | 2006-04-03 | 2011-08-30 | Stowers Institute For Medical Research | Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases |
| US20080267924A1 (en) | 2007-02-07 | 2008-10-30 | Vegenics Limited | Autologous lymph node transfer in combination with vegf-c or vegf-d growth factor therapy to treat secondary lymphedema and to improve reconstructive surgery |
| WO2010078624A1 (en) * | 2009-01-07 | 2010-07-15 | Vegenics Limited | Materials and methods for the treatment of hypertension |
-
2014
- 2014-02-14 JP JP2015557515A patent/JP6261617B2/ja not_active Expired - Fee Related
- 2014-02-14 US US14/765,133 patent/US20160000873A1/en not_active Abandoned
- 2014-02-14 EP EP14705566.9A patent/EP2956159A1/en not_active Withdrawn
- 2014-02-14 WO PCT/GB2014/050436 patent/WO2014125291A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Leblond et al. | Systemic and cardiac depletion of M2 macrophage through CSF-1R signaling inhibition alters cardiac function post myocardial infarction | |
| Bao et al. | Targeting tumor suppressor p53 for organ fibrosis therapy | |
| JP2018520646A5 (enExample) | ||
| JP2018538356A5 (enExample) | ||
| ES2637068T3 (es) | Composiciones que comprenden factores angiogénicos y métodos de uso de las mismas | |
| JP2018537087A5 (enExample) | ||
| JP2014533235A5 (enExample) | ||
| JP2019525744A5 (enExample) | ||
| Samuel et al. | Coadministration of adenoviral vascular endothelial growth factor and angiopoietin-1 enhances vascularization and reduces ventricular remodeling in the infarcted myocardium of type 1 diabetic rats | |
| JP2020073536A5 (enExample) | ||
| JP2017538680A5 (enExample) | ||
| Tuboly et al. | C5a inhibitor protects against ischemia/reperfusion injury in rat small intestine | |
| JP2017531613A5 (enExample) | ||
| JP2019534884A5 (enExample) | ||
| Nicolas et al. | Induction of experimental autoimmune orchitis in mice: responses to elevated circulating levels of the activin-binding protein, follistatin | |
| JP2017523239A5 (enExample) | ||
| RU2016108808A (ru) | Терапевтическое применение vegf-c и ccbe1 | |
| EP3169348B1 (en) | Pharmaceutical compositions comprising agonists of orexin-1 receptor ox1r for the treatment of inflammatory bowel diseases | |
| JP2020511415A (ja) | 線維症の処置のためのインターフェロン−ラムダの医学的使用 | |
| JP2006512284A5 (enExample) | ||
| CN110392691A (zh) | Hmgb1突变体 | |
| JP2018509423A5 (enExample) | ||
| JP2013529916A5 (enExample) | ||
| CA3157785A1 (en) | Polypeptides related to hmgb1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof | |
| JP6261617B2 (ja) | 嚢胞性腎疾患の処置に使用されるリンパ管新生を誘発する作用物質 |